Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARD103 |
Synonyms | |
Therapy Description |
ARD103 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CLEC12A (CLL1) that contains CD28 transmembrane and co-stimulatory domains and a CD3zeta activation domain, which may inhibit growth of CLL1-expressing tumor cells (JCO Global Oncol 2023 9: Supplement_1, 119). |